Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Baker said, “It requires a great healthy demand to ensure that it is going to be fit for every generic company.” “We all hope that the governments [across sub-Saharan Africa] Writing generic products in their budget for the future, but the reality is that we were relying on the donor fund at the interim. Even my country, South Africa, which has a good GDP and has 5 percent of its HIV reactions, is already buying antiratroviral for millions of millions millions. I will imagine that it will take them a few years to be able to raise money for Lenakapavir. “
Patients with Pepphor are now mainly concentrated on the treatment of existing patients, at the expense of resistance, physicians like Nomathmaba Chandiowana of South Africa’s Desmond Tutu Health Foundation will not start to increase infection rates that will not start to increase infection rates. Rather, the rate of infection will begin to rise, something that is on the African continent and beyond it A public health will affect.
Speaking at last week’s NCD Alliance Forum in Kigali, Chandiwana explained that the consequences of the new infection are not related to HIV. Research shows that people living in long-term HIV infections are even controlled by antheretroviral treatment, who are controlled by high blood pressure, obesity and type 2 diabetes, a burden of a disease that has already increased in sub-Saharan Africa. Chandiowana says, “HIV itself disrupts your metabolism, as many antieretroviral.” “We see the same chronic diseases among people living in HIV just like the general population, but at first age and in accelerated fashion.”
Because of this, a new generation of HIV treatment also requires a new generation and an idea is that Lenaakapavir is already used as the basis for future combination treatment for viruses. In addition to reducing some possible metabolic side effects, it was hoped that it could lead to the protocols of treatment that HIV -infected people do not need to take daily medicines.
Baker says, “Different ideas have been spread. “Can you combine the beamontholi cabotgravir with the injection of the six-month Lenakapavi? [as a form of viral suppression]So you will come six times a year for treatment, and will it be all injected? Works have a weekly antiratroviral pill and can you combine it with a six -month injection? It can be very free for humans, as they always tell us how stigmatizing the need to take daily drugs. “
Yet many of these studies are now in doubt, as unemployed say they were expected to be funded by US resources. “It’s not just Pepfer; We are also concerned about such ban on other types of research funds are being kept in the National Health Institutes, “he says.” It is only getting more difficult to move forward and advance progress. “
According to the anguor, it is still hoped that other donors may support global funding in Lenaacapavi’s collection, and unemployed say he is searching for new options for HIV resistance and research through European agencies, and probably searching for donor funds from Scandinavier sources, Japan, and Australia The At the same time, he believes that last month’s events have portrayed that African countries need to be able to be able to finance more preventive efforts themselves.
“Somehow Africa has to take action and contribute to the fight,” he said. “I think this is the big question. Through such countries, how much we can contribute to this continent that is not necessarily able to cover a lot of research and development but in the future is needed. “
At the same time, he is afraid that the unique opportunity provided by Lenakapavi can be lost without the same resources from the United States.
“It is incredible that we were just as a breakthrough,” he says. “I think it has been going back for many years and in the end we have to spend a lot more on public health expenses. Because in the end, if we can control this epidemic faster, it will save the planet more money in the long run and save lives. “
